Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

MS and infections risk | Multiple Sclerosis News Today | progressive MS| illustration of cells

Avonex (Interferon Beta-1a) for Multiple Sclerosis

Last updated May 10, 2022, by Teresa Carvalho, MS

Fact-checked by Ines Martins, PhD

FAQs about Avonex

Avonex was approved by the U.S. Food and Drug Administration in May 1996 for the treatment of adults with relapsing-remitting MS and active secondary progressive MS. Its use was expanded in 2003 to include clinically isolated syndrome. The Avonex Pen was approved in the U.S. in 2012.

Yes. While Avonex was previously not recommended for pregnant people, U.S. and European labels were updated in recent years to allow its use in pregnant and breastfeeding patients, where clinically necessary. The decisions were based on data from several European registries showing that exposure to interferon beta-based medications before conception or during the first trimester was not associated with fetal problems. However, people who plan to become pregnant should inform their healthcare provider and discuss the risks and benefits of continuing to receive this treatment during pregnancy.

Avonex may cause liver injury. As such, using this treatment with alcohol or other substances that also can damage the liver may increase the risk of liver problems. Patients who drink alcohol are advised to inform their healthcare providers before starting on this medication.

Some patients may see results as soon as six months after starting treatment. In the CHAMPS trial, which investigated Avonex against a placebo in nearly 400 patients with clinically isolated syndrome, a significant reduction in new brain lesions (both total and with active inflammation) could be observed as early as within six months. However, as each person may respond differently to a given medication, a discussion with a healthcare provider is recommended to better understand when and how Avonex is expected to help a particular patient.

While rare, hair loss and weight changes have been reported in clinical trials as possible side effects of Avonex. Individuals who experience such events should discuss these issues with their healthcare team.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Related Articles


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.